|

L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis

RECRUITINGPhase 3Sponsored by Tanta University
Actively Recruiting
PhasePhase 3
SponsorTanta University
Started2023-03-05
Est. completion2025-03-05
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05792527

Summary

This study aims at evaluating the possible efficacy and safety of L-carnitine in rheumatoid arthritis via targeting Jak/STAT pathway and TGF-β1

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria (9) i.e., 28 joints disease activity score (DAS-28) \>2.6.
* Patients receive the conventional DMARDs
* Both sexes.
* Age range between 18 and 70 years old.

Exclusion Criteria:

* Patients with heart disease (congestive heart failure, arrhythmia, hypertension, ischemic heart diseases), diabetes, active infection, other illness except rheumatoid arthritis.
* Patients with renal and hepatic dysfunction.
* Patients receiving biological DMARDs.
* Patients receiving oral prednisolone greater than 15 mg/day.
* Patients with hypersensitivity to study medications.
* Patients using antioxidants.
* Pregnant and lactating females.

Conditions2

ArthritisRheumatoid Arthritis

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.